Abstract

The atherogenicity theory for triglyceride-rich lipoproteins (TRLs; VLDL + intermediate density lipoprotein) generally cites the action of apolipoprotein C-III (apoC-III), a component of some TRLs, to retard their metabolism in plasma. We studied the kinetics of multiple TRL and LDL subfractions according to the content of apoC-III and apoE in 11 hypertriglyceridemic and normolipidemic persons. The liver secretes mainly two types of apoB lipoproteins: TRL with apoC-III and LDL without apoC-III. Approximately 45% of TRLs with apoC-III are secreted together with apoE. Contrary to expectation, TRLs with apoC-III but not apoE have fast catabolism, losing some or all of their apoC-III and becoming LDL. In contrast, apoE directs TRL flux toward rapid clearance, limiting LDL formation. Direct clearance of TRL with apoC-III is suppressed among particles also containing apoE. TRLs without apoC-III or apoE are a minor, slow-metabolizing precursor of LDL with little direct removal. Increased VLDL apoC-III levels are correlated with increased VLDL production rather than with slow particle turnover. Finally, hypertriglyceridemic subjects have significantly greater production of apoC-III-containing VLDL and global prolongation in residence time of all particle types. ApoE may be the key determinant of the metabolic fate of atherogenic apoC-III-containing TRLs in plasma, channeling them toward removal from the circulation and reducing the formation of LDLs, both those with apoC-III and the main type without apoC-III.

Highlights

  • The atherogenicity theory for triglyceride-rich lipoproteins (TRLs; VLDL 1 intermediate density lipoprotein) generally cites the action of apolipoprotein C-III, a component of some TRLs, to retard their metabolism in plasma

  • Because most actions on lipoprotein metabolism of apoC-III and apoE are contrary, if not directly antagonistic, the concomitant presence of apoCIII and apoE on the same TRL particle presents an obstacle to the understanding of the normal role of either apolipoprotein, as we found in a previous kinetic study [28]

  • In intermediate density lipoprotein (IDL), the percentage secreted as E2CIII2 increases substantially to 36% in normolipidemic subjects and 43% in hypertriglyceridemic subjects, the majority are still secreted as apoC-III-containing

Read more

Summary

Introduction

The atherogenicity theory for triglyceride-rich lipoproteins (TRLs; VLDL 1 intermediate density lipoprotein) generally cites the action of apolipoprotein C-III (apoC-III), a component of some TRLs, to retard their metabolism in plasma. The liver secretes mainly two types of apoB lipoproteins: TRL with apoC-III and LDL without apoC-III. Direct clearance of TRL with apoC-III is suppressed among particles containing apoE. ApoE may be the key determinant of the metabolic fate of atherogenic apoC-III-containing TRLs in plasma, channeling them toward removal from the circulation and reducing the formation of LDLs, both those with apoC-III and the main type without apoC-III.—Zheng, C., C. Rapid turnover of apolipoprotein C-III-containing triglyceride-rich lipoproteins contributing to the formation of LDL subfractions. ApoC-III is present on ?40–80% of triglyceride-rich lipoproteins (TRLs) and ?5–10% of LDLs in plasma [4,5,6]. The mechanisms by which apoC-III causes hypertriglyceridemia and atherosclerosis are incompletely understood

Objectives
Methods
Results
Conclusion

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.